^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IM19 CAR-T cells
i
Other names: IM19 CAR-T cells, IM19CAR-T cells, IM19, IM19 cells, IM19-CD28 CAR-T cells, IM19-41BB CAR-T cells, IM19 chimeric antigen receptor T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Imunopharm, Simcere
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
7ms
The pivotal clinical study of IM19 CAR-T cells in the treatment of relapsed or refractory aggressive B cell non-Hodgkin lymphomas (ESMO Asia 2023)
The incidences of CRS and neurotoxicity were 42% and 7%, respectively; no patient experienced grade 3-4 CRS or grade 3-4 neurotoxicity. Conclusions IM19 treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma can achieve a high rate of durable responses, with an extremely low incidence of grade 3 or more severe CRS and neurotoxicity.
Clinical • CAR T-Cell Therapy
|
IM19 CAR-T cells
2years
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. (PubMed, Chin J Cancer Res)
However, the median progression-free survival (mPFS) of 4-1BB-based product Kymriah was shorter than that of CD28-based Yescarta (2.9 monthsvs. 5.9 months), suggesting that Kymriah was limited in the long-term efficacy. Only one patient (4.5%) experienced grade 3 CRS and grade 3 neurotoxicity. These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T, IM19, which is promising for further development and clinical investigation.
Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • IM19 CAR-T cells
over2years
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma (clinicaltrials.gov)
P1/2, N=68, Not yet recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • fludarabine IV • IM19 CAR-T cells
over3years
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation (clinicaltrials.gov)
P=N/A, N=20, Recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd. | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
IM19 CAR-T cells
Share via
